Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tenofovir
Drug ID BADD_D02154
Description Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate.[A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog.[A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order to obtain oral bioavailability.[A18473, A178360]
Indications and Usage Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.[A178330] To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, [tenofovir alafenamide] and [tenofovir disoproxil].
Marketing Status experimental; investigational
ATC Code J05AF07
DrugBank ID DB14126
KEGG ID D06074
MeSH ID D000068698
PubChem ID 464205
TTD Drug ID D0D9HW
NDC Product Code Not Available
UNII 99YXE507IL
Synonyms Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine | 9-PMPA (tenofovir) | 9-(2-Phosphonomethoxypropyl)adenine | 9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer | 9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer | Tenofovir Disoproxil Fumarate | Disoproxil Fumarate, Tenofovir | Fumarate, Tenofovir Disoproxil | Tenofovir Disoproxil | Disoproxil, Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098 | (R)-9-(2-phosphonylmethoxypropyl)adenine | Viread
Chemical Information
Molecular Formula C9H14N5O4P
CAS Registry Number 147127-20-6
SMILES CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chromaturia20.02.01.0020.018418%
Deafness04.02.01.0010.007173%Not Available
Death08.04.01.001--
Decreased activity19.11.01.002; 08.01.01.0060.006786%Not Available
Dementia19.20.02.001; 17.03.01.001--Not Available
Dementia Alzheimer's type17.03.06.001; 19.20.03.0010.001939%Not Available
Depression19.15.01.001--
Dermatitis23.03.04.0020.002908%Not Available
Dermatitis allergic10.01.03.014; 23.03.04.0030.001939%Not Available
Dermatitis bullous23.03.01.0020.004265%
Diabetes insipidus14.05.07.003; 05.03.03.0040.002908%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.012020%Not Available
Diarrhoea07.02.01.001--
Diffuse large B-cell lymphoma16.28.02.001; 01.15.02.0010.001939%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.006--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.004847%Not Available
Drug interaction08.06.03.0010.022683%Not Available
Dry eye06.08.02.0010.010857%
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.036060%
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.0020.014153%
Electrolyte imbalance14.05.01.0020.001939%Not Available
Encephalopathy17.13.02.0010.005816%
Erythema multiforme23.03.01.003; 10.01.03.0150.003877%
Eyelid ptosis17.17.02.004; 06.05.01.0020.001939%Not Available
Fanconi syndrome03.06.01.001; 20.05.03.009; 14.01.01.011--Not Available
Fatigue08.01.01.002--
Feeling jittery08.01.09.0160.006592%Not Available
Flatulence07.01.04.002--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene